A case–control study involving 200 MS patients and 200 healthy controls in a subset of Iranian population reported that the rs12044852 polymorphism of CD58 has a profound effect on the onset of MS but not significantly associated with patients’ gender, disease severity and type of MS [29]. This evidence concerns the gene CD58 and myeloid sarcoma.